Compare MP & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MP | RGEN |
|---|---|---|
| Founded | 2017 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.6B |
| IPO Year | 2020 | 1995 |
| Metric | MP | RGEN |
|---|---|---|
| Price | $56.13 | $176.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $75.25 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 6.8M | 971.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.28 | ★ 286.96 |
| EPS | N/A | ★ 0.24 |
| Revenue | ★ $331,952,000.00 | $141,236,000.00 |
| Revenue This Year | $100.51 | $14.30 |
| Revenue Next Year | $60.41 | $14.52 |
| P/E Ratio | ★ N/A | $758.46 |
| Revenue Growth | ★ 147.15 | 35.10 |
| 52 Week Low | $37.81 | $100.99 |
| 52 Week High | $100.25 | $188.73 |
| Indicator | MP | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 66.61 |
| Support Level | $56.20 | $156.65 |
| Resistance Level | $57.46 | $188.73 |
| Average True Range (ATR) | 3.38 | 6.21 |
| MACD | 0.26 | 0.29 |
| Stochastic Oscillator | 38.61 | 62.11 |
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.